A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Efficacy of RC1416 Injection in Patients With Moderate to Severe Asthma
Latest Information Update: 09 Apr 2025
At a glance
- Drugs RC 1416 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Regenecore Biotech
- 09 Apr 2025 New trial record